dc.contributor | IDIAP Jordi Gol |
dc.contributor.author | Castellsagué, Jordi |
dc.contributor.author | Calingaert, Brian |
dc.contributor.author | Bui, Christine |
dc.contributor.author | Varas-Lorenzo, Cristina |
dc.contributor.author | Arana, Alejandro |
dc.contributor.author | Gonzalez-Rubio, Francisca |
dc.contributor.author | Linder, Marie |
dc.contributor.author | Citarella, Anna |
dc.contributor.author | Scholle, Oliver |
dc.contributor.author | Blenk, Tilo |
dc.contributor.author | Garbe, Edeltraut |
dc.contributor.author | Giner-Soriano, Maria |
dc.contributor.author | Roso-Llorach, Albert |
dc.contributor.author | Poblador-Plou, Beatriz |
dc.contributor.author | Prados-Torres, Alexandra |
dc.contributor.author | Perez-Gutthann, Susana |
dc.date.accessioned | 2017-03-30T10:10:53Z |
dc.date.available | 2017-03-30T10:10:53Z |
dc.date.issued | 2017-01-30 |
dc.identifier.citation | Castellsague J, Perez-Gutthann S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, et al. Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiol Drug Saf. 2017 Jan 30 |
dc.identifier.uri | https://hdl.handle.net/11351/2733 |
dc.language.iso | eng |
dc.publisher | Pharmacoepidemiology and Drug Safety. Published by John Wiley & Sons Ltd. |
dc.rights | Atribución-NoComercial-SinDerivadas 3.0 España |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ |
dc.source | Scientia |
dc.subject | Farmacologia |
dc.subject | Medicaments - Efectes secundaris |
dc.subject | Claudicació intermitent |
dc.subject.mesh | Peripheral Arterial Disease |
dc.subject.mesh | Pharmacoepidemiology |
dc.subject.mesh | Intermittent Claudication |
dc.title | Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/pds.4167 |
dc.subject.decs | arteriopatía periférica |
dc.subject.decs | farmacoepidemiología |
dc.subject.decs | claudicación intermitente |
dc.relation.publishversion | http://onlinelibrary.wiley.com/doi/10.1002/pds.4167/full |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | (Castellsague J, Perez-Gutthann S, Varas-Lorenzo C, Arana A) Department of Epidemiology, RTI Health Solutions, Barcelona, Spain |
dc.contributor.authoraffiliation | (Calingaert B, Bui C) Department of Epidemiology, RTI Health Solutions, Durham, NC, USA. |
dc.contributor.authoraffiliation | (Prados-Torres A, Poblador-Plou B, Gonzalez-Rubio F) EpiChron Research Group on Chronic Diseases, IIS Aragón, Aragon Health Sciences Institute (IACS), REDISSEC, Zaragoza, Spain. |
dc.contributor.authoraffiliation | (Giner-Soriano M, Roso-Llorach A) Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Spain. |
dc.contributor.authoraffiliation | (Linder M, Citarella) Centre for Pharmacoepidemiology, Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. |
dc.contributor.authoraffiliation | (Scholle O, Blenk T, Garbe E) Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany |
dc.identifier.pmid | 28133890 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |